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Purpose: High-risk prostate cancer is a potentially lethal disease that is increasing in the diagnosis of prostate
cancer patients. Compared to other prostate cancer patients (medium or low risk), management, diagnosis and
treatment are not as successful among high-risk patients. Because the genetic characterization of prostate
cancer patients is increasing, we aimed to determine whether genetic information in one of the primary
associated genes, such as RNASEL (2', 5'-oligoadenylate-dependent RNase L), could be used as a biomarker to
improve the quality of life and treatment among high-risk patients. The main objective is to identify genetic
variants of RNASEL that could be associated with high-risk prostate cancer to improve the clinical managing of
these patients.
Methods: A total of 231 prostate cancer patients were genotyped for 7 variants of RNASEL gene. Clinical
information was obtained from medical examinations and genetic analysis (amplification and sequencing 7
variants of RNASEL gene) were performed by the researchers. Data were processed by statistical analysis
(Chi square and logistic regression) using SPSS v.15.0.
Results: Comparisons between genotypes and clinical characteristics of patients revealed that individuals with
GG in D541E, AA in R462Q and AG in I97L in RNASEL gene were high-risk patients according to the European
Urology Guidelines.
Conclusions: Genotyping the RNASEL gene with routine diagnostic techniques could confer a more precise
diagnosis of high-risk prostate cancer patients and increase the diagnostic accuracy above the current rate of
70% due to the relation between the genetic variants of RNASEL gene and the risk of this cancer.
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Prostate cancer (PCa) is the most commonly diagnosed
cancer among men worldwide, with almost one million
new cases each year. However, the exact definition of
high-risk prostate cancer remains unclear. A consensus on
a clear definition is still needed, which currently translates
into a lack of specific patient counseling and clear treat-
ment management (Bastian et al. 2012). The actual risk* Correspondence: msaiz@ugr.es
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reproduction in any medium, provided the origstratification of prostate cancer is based on the probability
of recurrence after local treatment. Some pre-treatment
parameters have been analyzed as potential prognostic
factors. PSA and Gleason score are considered as pre-
treatment parameters that, when combined with clinical
stage, are used to provide a more accurate prognosis of
the results in these patients.
Prostate cancer is currently classified as stages T1 and
T2 in located PCa and locally advanced prostate cancer is
classified into stages T3-T4. Today, according to the EAU
(European Association of Urology) and AUA (American
Urology Association) guidelines, radical prostatectomy is
a reasonable treatment option for selected PCa patients. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
Table 1 Characteristics of the studied population
n = 231
Mean (SD1) age (years) 66.9 (7.74)
Stage
1 n = 9 (3.90%)
2 n = 140 (60.60%)
3 n = 47 (20.35%)
4 n = 23 (9.96%)
Missing n = 12 (5.02%)
Gleason score
2-6 n =145 (62.77%)
7 n = 43 (18.61%)
8-10 n = 28 (12.12%)
Missing n = 15 (6.27%)
PSA levels (ng/ml)
≤ 4.0 n = 1 (0.42%)
4.1-10 n = 98 (42.42%)
10.1-20 n = 63 (27.27%)
> 20 n = 40 (17.32%)
> 1,000 n = 2 (0.84%)
Missing n = 27 (11.69%)
n (number of patients), SD (standard deviation).
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(Bastian et al. 2012). However, a better knowledge of the
natural history of the disease and developments in treat-
ment options have resulted in more sophisticated risk stra-
tification systems (Marciscano et al. 2012). It is clinically
important to identify patients with high-risk PCa early on
because they will benefit the most from curative therapy
(Bastian et al. 2012). Currently, systemic therapy has a lim-
ited role in the treatment of localized prostate cancer, al-
though adjuvant androgen deprivation therapy (ADT) has
yielded significant improvement in disease-free survival for
men with high-risk features treated with definitive radiation
and a significant overall survival advantage for men with
Gleason scores of 8 or higher (Dorff et al. 2011).
There are two primary types of treatment: watchful
waiting and radiotherapy. However, neither carries 100%
accuracy. Furthermore, no randomized studies have com-
pared more intensive treatments, such as radiotherapy or
surgery, with watchful treatment. A combination of radio-
therapy with androgenic deprivation treatment over a short
period is highly recommended based on the results of a
randomized Phase III trial (D'Amico et al. 2008). Many
different diagnostic methods are available and are widely
used in high-risk patients, including local staging (T-stage),
computed tomography (CT), magnetic resonance imaging
(MRI), digital rectal examination (DRE), transrectal ultra-
sonography (TRUS) and 11C-choline positron emission
tomography (PET). Unfortunately, none of these methods
offers greater than 70% accuracy (Rinnab et al. 2007).
Currently, genetic, environmental and dietary factors are
considered as the main components of PCa risk, playing
large roles in the etiology of this cancer. Some specific
SNPs in the involved genes, such as RNASEL at 1q24-25
(also known as Hereditary Prostate Cancer gene 1 (HPC1)),
have been related to an increased risk of developing pros-
tate cancer (Alvarez-Cubero et al. 2012; Agalliu et al. 2010;
Meyer et al. 2010). The use of genetic information (as bio-
markers) in combination with clinical details could be used
by specialists to provide genetic counseling to these patients
and adjust their treatment. The main goal of this article
was to identify an alternative biomarker that could be used
to identify patients with high-risk prostate cancer.
Materials and methods
Participant recruitment
Participants were recruited from the Urology Service of
the University “Hospital Virgen de las Nieves”, Granada,
Spain from 2007 to 2011.
Ethics statement
This study complied with the Declaration of Helsinki.
Informed consent was obtained from all subjects before
they were enrolled in the study. The study and use of
archive samples for this project were approved by theEthics Committee of the University “Hospital Virgen de
las Nieves,” Granada, Spain.Participants
A total of 231 patients (histopathologically confirmed after
abnormal serum PSA findings) were enrolled. The patients’
clinical information was noted by a urologist, who also
made annotations about important parameters for prostate
cancer, such as PSA, local stage (T-score), Gleason score,
and demographic information, such as age and place of
birth (see Table 1).
The mean participant age was approximately 66.9 (SD =
7.74) years. Demographic information was also collected
to know that all the participants were unrelated Caucasian
men. Due to the characteristics of this pathology, all of the
participants were men.Mutation detection
Genomic DNA was extracted from blood samples using
an organic extraction procedure with phenol/chloroform/
isoamyl alcohol and proteinase K. In all participants, the
RNASEL gene was amplified and sequenced with specific
primers designed to cover the main variants of this gene
that are related to prostate cancer development (R462Q,
D541E, E262X, 471delAAAG, G265X, M1I and I97L). All
detected mutations were confirmed independently in this
study.
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Subjects were included as high-risk patients if they met
the following indications of the European Association of
Urology (EAU) Guidelines:
 Local stage with values ≥T2c;
 Gleason score > 7; or
 PSA > 20 ng/ml.
The National Comprehensive Cancer Network (NCCN)
includes patients with T3 stage, a Gleason score ranging
from 8–10 or PSA values > 20 ng/ml. A total of 217 pa-
tients meet these criteria and were catalogued as high risk
patients.
In our design we have included NCCN as the risk clas-
sification system for classify our data.
In the first steps of the analysis, we determined which
of the seven analyzed variants of the RNASEL gene
(R462Q, D541E, E262X, 471delAAAG, G265X, M1I and
I97L) differed between subjects (low and intermediate-
risk PCa patients (control group) and high-risk PCa pa-
tients (case group)) and could be used as biomarkers forFigure 1 Distribution of patients in three risk groups. a) According to
and d) According to E.U. A Guidelines and meeting all three criteria togethhigh-risk patients. We then conducted a case-case ana-
lysis among high-risk PCa patients to establish which of
the variants associated with prostate cancer risk were
also associated with a high-risk phenotype.
Statistical analysis
Allele frequencies were calculated by gene counting
method for all of the studied SNPs. Variants E262X,
471delAAAG, G265X and M1I were not further consid-
ered for statistical analysis due to the presence of only
one genotype in the entire patient population. For each
single nucleotide polymorphism (SNP), including R462Q
(rs486907), D541E (rs627928) and I97L (rs56250729),
the allele frequencies were compared using the χ2 test in
SPSS v.15.0 (IBM SPSS Statistics 2011). The Hardy-
Weinberg equilibrium test and an analysis of the linkage
of the loci of the RNASEL gene were performed with
ARLEQUIN v.3.5 software (Excoffier & Lischer 2010).
Comparisons between each locus and clinical information,
such as PSA (≤ 4.0, 4.1-10, 10.1-20, > 20, > 1,000 ng/ml),
age (≤ 55, 56–60, 61–65, > 65 years), stage (1, 2, 3, 4) and
Gleason score (2–6, 7, 8–10), were obtained withlocal stage; b) According to gleason score; c) According to PSA levels;
er.
Table 2 Descriptive statistical analyses of the patients and the clinical parameters with the RNASEL gene SNPs
(R462Q, D541E and I97L)
SNP Age (years) PSA values Gleason score T- stage
median (SD) median (SD) median (SD) median (SD)
R462Q-rs486907 AA 65.5 (8.64) 16 (429.92) 6 (1.63) 3 (0.78)
GA 67 (7.75) 10.01 (201.81) 6 (1.25) 2 (0.68)
GG 67 (7.25) 9.6 (15.44) 6 (1.07) 2 (0.56)
D541E-rs627928 GG 68 (8.26) 12.2 (388.05) 6 (1.44) 3 (082)
TG 67 (7.84) 10 (20.25) 6 (1.21) 2 (0.67)
TT 67 (6.19) 10 (6.57) 6 (0.95) 2 (0.35)
I97 L-rs56250729 TT 67 (7.83) 10.35 (157.94) 6 (1.29) 2 (0.71)
GT 65 6.43 6 2
GG 70 9.49 7 2
SD (standard deviation).
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and Fisher’s exact test; an ANOVA was also performed
with the data. All tests considered the nominal statistical
significance (p-value) to be <0.05. To evaluate correlations
between high-risk patients and genetic characteristics, a χ2
test was first performed among high-risk patients (Gleason
score > 7, PSA > 20 ng/ml or T-stage > 2). An adjustment
for each genotype was then conducted for AA and AG in
R462Q and GG and TG in D541E using a logistic regres-
sion analysis.Results
We could have included patients with a Gleason score
above 7 (12.13%), a stage above 2 (30.54%) or a PSA
value > 20 ng/ml (18.41%) as high-risk patients. Any of
these single clinical factors could place a patient in a
high-risk group, but this would have increased the per-
centage of individuals in this group (93.93%) (Figure 1).
A more in-depth analysis was performed among the ge-
notypes and all patients’ clinical characteristics (Table 2).Table 3 The distribution (%) of high-risk patients among the
RNASEL gene, X2 statistical p-values










AA 47.2 (17) 33.3 (12) 45.4 (15) 3
GA 13.8 (16) 8.6 (10) 14.6 (16) 0
GG 21.3 (16) 2.7 (2) 15.9 (11) 0
D541E-rs627928
GG 35.1 (26) 20.3 (15) 29.0 (20) 2
TG 16.7 (20) 7.5 (9) 16.5 (18) 0
TT 9.1 (3) 0.0 12.1 (4) 0
p-value1: derived from Pearson chi-square test.
p-value2: adjusted for high-risk patients by logistic regression.
OR: odds ratio.
CI: Confidence Interval.We examined the genotypes that could indicate high-
risk PCa to include them as biomarkers with the clinical
parameters. Only R462Q, D541E and I97L presented dif-
ferent genotypes among the patient population. The
remaining SNPs (E262X, 471delAAAG, G265X, and
M1I) could not be included in the analysis because only
one genotype was identified among all of the patients.
Among the variants with statistically significant values,
the genotypes associated with the worst prognoses and
included in the recruitment for high-risk patients were
GG in D541E, AA in R462Q and TG in I97L. The SNP
distribution is summarized in Table 3. However, the vari-
ants that were associated with better clinical (Gleason
score ≤ 7; PSA values < 20 ng/ml; T-stage < 3) characteris-
tics were TT in D541E and GG in R462Q. We analyzed
the clinical parameters among all of the patients, between
the SNPs and clinical parameters, and most of the results
were statistically significant (Additional file 1: Table S1). In
high-risk patients, the p-values were statistically significant
in R462Q and D541E (p ≤ 0.001) but not in I97L (p =
0.565) (Table 3). After correction using a logistic regressiondifferent SNP genotypes (R462Q and D541E) of the
Gleason score
> 7% (n)
P-value1 P-values2 OR (95% CI)
1000
ml% (n)
.03 (1) 33.3 (12)
≤ 0.001
0.003 0.161 (0.048-0.543)
.9 (1) 8.3 (10) 0.271 1.511 (0.724-3.153)
.0 (0) 6.8 (5) - -
.9 (2) 21.6 (16)
≤ 0.001
0.017 0.205 (0.056-0.755)
.0 (0) 9.4 (11) 0.081 0.340 (0.101-1.142)
.0 (0) 0.0 (0) - -
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R462Q variants lost significance. However, the high-risk
phenotypes AA in R462Q (p = 0.003) and GG in D541E
(p = 0.017) were statistically confirmed (Table 3).
Discussion
Currently, the diagnosis of high-risk prostate cancer has
approximately 70% accuracy. A digital rectal examination
often underestimates the tumor extent; a positive correl-
ation between the results of digital rectal examinations
and pathological tumor stage was found in fewer than 50%
of cases. The most commonly used method for viewing
the prostate is transrectal ultrasound. However, only 60%
of tumors are visible with transrectal ultrasound, and it
was no more accurate at predicting organ-confined disease
than digital rectal examination (Smith et al. 1997). Both
computed tomography (CT) and magnetic resonance im-
aging (MRI) are now of a high technical standard, but nei-
ther modality is sufficiently reliable to make their use
mandatory in the assessment of local tumor invasion
(Jager et al. 2000). Endorectal MRI (e-MRI) may allow for
more accurate local staging by complementing the existing
clinical variables by improving the spatial characterization
of the prostatic zonal anatomy and molecular changes
(Masterson & Touijer 2008). Image quality and localization
improves significantly with e-MRI compared with external
coil MRI (Mullerad et al. 2005). The overall accuracy of
11C-choline positron emission tomography (PET) in defin-
ing local tumor stage (pT2 and pT3a-4) has been reported
to be approximately 70%. The treatment options that are
currently available for locally advanced prostate cancer are
watchful waiting and radiotherapy. Watch waiting might
be a treatment option for selected patients with non-poorly
differentiated T3 tumours and a life expectancy of less than
10 years. Concomitant and adjuvant hormonal therapy for
a total duration of 2–3 years, with external beam irradiation
is recommended because it improves overall survival. Rad-
ical prostatectomy is optional in selected patients, in the
context of multimodality treatment.
Many genes have been studied in order to determine a
marker to be used as a diagnosis and prognosis factor
among patients with prostate cancer. Among all the
genes described as relevant in the developing of prostate
cancer, the RNASEL gene has been highlighted as having
the greatest effect (Alvarez-Cubero et al. 2012; Meyer
et al. 2010). It has been recently determined that RNASEL
gene variants D541E, R462Q and I97L are relevant muta-
tions in the prognosis of the cancer (Alvarez-Cubero et al.
2012; Shook et al. 2007). Through the analysis of these
variants and its correlation with clinical characteristics, it
has been identified that genotypes with a worst prognoses
(associated to individual who present clinical characteris-
tics classified as high risk) were GG in D541E and AA in
R462Q, whereas the ones that represented better clinicalcharacteristics were TT in D541E, GG in R462Q and AC
in I97L. A similar study in R462Q has been carried out in
other populations, such as in Cleveland, Ohio and Detroit,
Michigan, where men who are heterozygous with respect
to the mutated allele were found to have a 50% greater risk
of prostate cancer than non-carriers, and homozygotes had
more than double the risk (Casey et al. 2002). Good results
have been obtained with RNASEL gene but, as prostate
cancer is a polygenic cancer, many other genes have to be
analyzed and that will confer accurate information.
Even though genetic markers have been related to pros-
tate cancer long time ago; none of them are currently used
in clinical diagnosis. Though clinical diagnosis has not
higher accuracy of 70%, these types of diagnosis or progno-
sis factors are not still used as a routine. The combination
of anatomopathological, radiological techniques and genetic
testing of genes related to prostate cancer will help clini-
cians both to better diagnose the type of cancer in each pa-
tient and to give a more specific treatment to them. That is
why; we suggest the use of three SNPs in RNASEL gene as
a combination factor with the present clinical sources.
Conclusions
If the genetic information obtained in this study were
added to the current diagnostic criteria, we could offer
more specific treatment and increase the diagnostic ac-
curacy above the current rate of 70%. However, we are
conscious of the limited number of patients in this ana-
lysis, we suggest to make a deeper study by increasing the
number of patients in this and others genes that have been
already related to prostate cancer diagnosis and prognosis,
to have a more accurate confirmation of the results. Both
genetic and clinical data could confer relevant information
about the control of prostate cancer. As mentioned in the
results, individuals with GG in D541E, AA in R462Q and
AG in I97L, in the RNASEL gene are classified as high-
risk patients. Therefore, including RNASEL genotyping as
an analytic parameter could confer a more accurate diag-
nosis in high-risk prostate cancer patients.
Additional file
Additional file 1: Table S1. X2 statistical p-values for all of the patients
(SNPs: R462Q, D541E and I97L of the RNASEL gene).
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